Patent · US Active

Bispecific EGFR/CD16 antigen-binding protein

US11510972B2 · kind B2 · utility

1Cited by

0References

16Claims

0Family size

Assignee

AFFIMED GMBH · DE

Inventors

Michael Kluge · Heidelberg, DE
Michael Tesar · Heidelberg, DE
Ivica Fucek · Hattersheim, DE
Kristina Ellwanger · Heidelberg, DE
Uwe Reusch · Maikammer, DE
Michael Damrat · Heidelberg, DE
Erich Rajkovic · Schriesheim, DE
Martin Treder · Heidelberg, DE

Key dates

Filing date	Sep 2, 2020
Grant date	Nov 29, 2022
Priority date	—
Expiry date	Nov 23, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Described are tetravalent, bispecific EGFR/CD16A antigen-binding proteins for engaging NK-cells towards EGFR-positive cells. EGFR/CD16A antigen-binding proteins with different pharmacokinetic (PK) properties are described. Further described is the use of bispecific EGFR/CD16A antigen-binding proteins for the treatment of an EGFR-positive malignancy, such as EGFR-positive tumors.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.